Likes Subject
How did that work out for you? VelvetJones 08/02/19 12:04 AM
Dew, Thanks, my friends are not in the makedrysgreatagain 05/24/19 10:15 PM
Hi. There are several approved drugs approved for DewDiligence 05/22/19 11:17 AM
I an doing some research into Dendrion for makedrysgreatagain 05/20/19 9:02 PM
No volume, no revenue, no information, debt issues eddy2 05/18/16 10:07 AM
A ATCrunch 05/17/16 8:07 PM
DNDN from LONG AGO... since someone posted it Crazy Money 11/10/15 2:28 AM
Don't think so... :-) Crazy Money 11/10/15 2:18 AM
one of the worst collapses in stock market power_forward 08/04/15 9:42 AM
It is still $45 if you take in eddy2 08/03/15 2:31 PM
Link to bankruptcy information: sidedraft 07/08/15 6:32 PM
The final nail, from today at Fidelity: sidedraft 06/13/15 2:21 PM
I'm waiting for it to reach par status eddy2 06/13/15 2:01 PM
Chapter 11 is money owed to owners where eddy2 06/13/15 2:00 PM
Waiting for the dust to settle....all Q can't 98040 06/11/15 2:12 PM
Bankruptcy Plan Effective/Shares Cancelled 06/11/2015 sidedraft 06/11/15 10:34 AM
we may see it at .45 very soon! armo 06/09/15 12:06 PM
This was once 45.00 a share lmao at power_forward 06/09/15 11:00 AM
Going long and strong.....high risk high reward....that's the 98040 06/07/15 2:55 PM
DNDNQ to open over a dime on Monday! armo 06/05/15 11:51 AM
Will see what happens on the 9th :) 98040 06/05/15 11:48 AM
Going long and strong last shake out for 98040 06/04/15 6:35 PM
Read doc 738 ;) 98040 05/31/15 2:14 PM
Going long and strong unsecured holders will receive 98040 05/31/15 1:51 PM
docket 714 is interesting, what do you think Qmark 05/31/15 1:41 PM
Wake wake it's almost June or maybe July 98040 05/28/15 2:35 PM
http://www.fasb.org/jsp/FASB/Document_C/DocumentPage?cid=1218220130001&acceptedD eddy2 05/12/15 11:21 AM
Looks good on paper. Moved on guys see eddy2 05/05/15 2:02 PM
They don,t tell you stuff like that. If eddy2 05/02/15 11:49 AM
Hmmmmmmm let me know when you find out :) 98040 04/30/15 12:01 PM
What year? eddy2 04/30/15 11:16 AM
Patient wake me up in June :) 98040 04/29/15 11:37 PM
Still holding no bids and no asks? She eddy2 04/29/15 8:55 AM
https://www.youtube.com/watch?t=20&v=3CsAal0iRvg This is to funny. eddy2 04/22/15 8:55 AM
http://www.deonsupply.com/ Fighting cancer by taking the recycled oil proce eddy2 04/22/15 8:53 AM
http://en.wikipedia.org/wiki/Automotive_oil_recycling Did you now that the eddy2 04/22/15 8:49 AM
http://medicinehatnews.com/alberta-election/stories-features/2015/04/15/independ eddy2 04/16/15 9:55 AM
Not my first rodeo :) 98040 04/15/15 5:35 PM
http://www.financialstabilityboard.org/multimedia/fsb-chairs-opening-remarks-at- eddy2 04/15/15 5:26 PM
http://www.financialstabilityboard.org/2011/01/cos_051201/ eddy2 04/15/15 5:23 PM
http://www.financialstabilityboard.org/about/fsb-members/ I would read th eddy2 04/15/15 5:20 PM
Apr 13, 2015 13:54:00 (ET) 98040 04/15/15 4:20 PM
https://www.youtube.com/watch?v=EeidGrTwdEU eddy2 04/15/15 4:04 PM
Taking her to the bank today. eddy2 04/15/15 3:44 PM
ready to take off? kraken17 04/15/15 3:09 PM
Looks like those bag holders will be receiving 98040 04/13/15 2:58 PM
https://www.youtube.com/watch?v=S9RdM1ytJIY eddy2 04/12/15 12:16 PM
https://www.youtube.com/watch?v=MJbBSIFN36k eddy2 04/12/15 11:55 AM
Its trading over $.04 down to $.03 how eddy2 04/11/15 4:33 PM
why didn't nol's save the shareholders? stockanalyze 04/08/15 10:32 PM
Likes Subject

VelvetJones
08/02/19 12:04 AM
makedrysgreatagain
05/24/19 10:15 PM
DewDiligence
05/22/19 11:17 AM
makedrysgreatagain
05/20/19 9:02 PM
ATCrunch
05/17/16 8:07 PM
A
Crazy Money
11/10/15 2:28 AM
Crazy Money
11/10/15 2:18 AM
power_forward
08/04/15 9:42 AM
eddy2
08/03/15 2:31 PM
sidedraft
07/08/15 6:32 PM
sidedraft
06/13/15 2:21 PM
armo
06/09/15 12:06 PM
power_forward
06/09/15 11:00 AM
armo
06/05/15 11:51 AM
98040
06/05/15 11:48 AM
98040
05/31/15 2:14 PM
eddy2
05/02/15 11:49 AM
eddy2
04/30/15 11:16 AM
98040
04/29/15 11:37 PM
98040
04/15/15 5:35 PM
98040
04/15/15 4:20 PM
eddy2
04/15/15 3:44 PM
kraken17
04/15/15 3:09 PM
stockanalyze
04/08/15 10:32 PM

Dendreon Corp fka DNDNQ

Followers
225
Posters
917
Posts (Today)
0
Posts (Total)
12660
Created
07/17/05
Type
Free
Moderators

DENDREON  http://www.dendreon.com/

Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization, and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering, and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 and by the European Medicines Agency in 2013. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and has manufacturing facilities in Georgia and California.
 

 

PAVING A NEW PATH FOR TREATING CANCER

PROVENGE® (sipuleucel-T) is the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. PROVENGE is designed to take the body’s own immune cells and reprogram them to attack advanced prostate cancer.

Important Safety Information

PROVENGE full Prescribing Information

For more information about PROVENGE, please visit www.PROVENGE.com.

US Health Care Professionals can visit the Medical Affairs Web site to submit a request online.

http://www.dendreon.com/products/provenge/manufacturing/
http://www.dendreon.com/products/provenge/scientific_publications/
 

PATIENT RESOURCES

The Patient Resources section includes information about patient access, clinical trials and patient information.

For Questions about PROVENGE® (sipuleucel-T), contact Dendreon ON Call:
Phone: 877-336-3736
Fax: 877-556-3737

http://www.dendreon.com/patient_resources/patient_access/
 

CLINICAL TRIALS

Dendreon has several ongoing clinical trials, including:

Sipuleucel-T Clinical Trials

P10-1

  • An Open-Label, Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated with Sipuleucel-T on Dendreon Study P-11
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P10-2

  • A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Non-Metastatic Prostate Cancer and a Rising Prostate Specific Antigen After Primary Therapy.
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P10-3 (called PROCEED)

  • A Registry of Sipuleucel-T in Men with Advanced Prostate Cancer (called PROCEED) to Further Evaluate Safety and Survival Associated with Sipuleucel-T
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P11-1

  • An Open-Label Study of Sipuleucel-T in European Men with Metastatic, Castrate Resistant Prostate Cancer
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P11-3

  • A Randomized, Open-Label, Phase 2 Trial of Sipuleucel-T with Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men with Metastatic Castrate Resistant Prostate Cancer
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P11-4 (PRIME)

  • Immune Monitoring Protocol in Men with Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P12-1

  • An Observational Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Metastatic Disease in Castrate-Resistant Prostate Cancer
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P12-2

  • A Randomized, Open-Label, Phase 2 Trial Examining Combination Therapy with Sipuleucel-T and Enzalutamide in Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer.
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

Additional ACI Product Candidate Clinical Trials

N10-1 (called Neu-ACT)

  • A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
    To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

    

PATIENT INFORMATION

To find out more about cancer and specifically prostate cancer, we have provided a list of patient-focused cancer organizations.

Pipeline

POTENTIAL NEW CANCER THERAPIES ON THE HORIZON

Investigational product candidates in the Dendreon pipeline include:

 

Investor Relations

Stock Quote (NASDAQ: DNDN)
Price:
2.04
Change:
+ 0.03
Volume:
1,783,600
4:00 PM ET on Jun 13, 2014
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph
3 Mo.   6 Mo.   1 Yr.

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

View all »   RSSRecent Releases

http://investor.dendreon.com/stockquote.cfm
http://investor.dendreon.com/media.cfm
http://investor.dendreon.com/events.cfm
http://investor.dendreon.com/sec.cfm
http://investor.dendreon.com/analysts.cfm
http://investor.dendreon.com/annuals.cfm
http://investor.dendreon.com/investorkit.cfm
http://investor.dendreon.com/alerts.cfm


$DNDN Charts:





 
 

 

Most Liked Posts
(Last 30 Days)
Board Info
Posts Today
0
Posts (Total)
12660
Posters
917
Moderators
Most Liked Posts
(Last 30 Days)
New Post